Osteoporosis: Challenges and new opportunities for therapy

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones. It causes a significant amount of morbidity and mortality in patients and is often only diagnosed after a fracture occurs. This review will highlight recent advances in the development of novel anabolic approaches for treatment of osteoporosis, such as parathyroid hormone (PTH), calcium sensing receptor modulators, statins and prostanoid receptor agonists. Selected antiresorptive targets (cathepsin K inhibitors and vitronectin receptor antagonists) will also be surveyed.

Original languageEnglish
Pages (from-to)477-486
Number of pages10
JournalCurrent Opinion in Drug Discovery and Development
Volume5
Issue number4
StatePublished - 1 Jul 2002

Fingerprint

Osteoporosis
Integrin alphaVbeta3
Cathepsin K
Calcium-Sensing Receptors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Bone and Bones
Parathyroid Hormone
Prostaglandins
Chronic Disease
Morbidity
Mortality
Therapeutics

Keywords

  • Anabolic therapy
  • Calcium sensing receptor
  • Cathepsin K inhibitors
  • Osteoporosis
  • Parathyroid hormone
  • Prostanoids
  • Statins
  • Vitronectin antagonists

Cite this

@article{c60580b3501342f584bbdae0b20e9fae,
title = "Osteoporosis: Challenges and new opportunities for therapy",
abstract = "Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones. It causes a significant amount of morbidity and mortality in patients and is often only diagnosed after a fracture occurs. This review will highlight recent advances in the development of novel anabolic approaches for treatment of osteoporosis, such as parathyroid hormone (PTH), calcium sensing receptor modulators, statins and prostanoid receptor agonists. Selected antiresorptive targets (cathepsin K inhibitors and vitronectin receptor antagonists) will also be surveyed.",
keywords = "Anabolic therapy, Calcium sensing receptor, Cathepsin K inhibitors, Osteoporosis, Parathyroid hormone, Prostanoids, Statins, Vitronectin antagonists",
author = "Rotella, {David P.}",
year = "2002",
month = "7",
day = "1",
language = "English",
volume = "5",
pages = "477--486",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "4",

}

Osteoporosis : Challenges and new opportunities for therapy. / Rotella, David P.

In: Current Opinion in Drug Discovery and Development, Vol. 5, No. 4, 01.07.2002, p. 477-486.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Osteoporosis

T2 - Challenges and new opportunities for therapy

AU - Rotella, David P.

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones. It causes a significant amount of morbidity and mortality in patients and is often only diagnosed after a fracture occurs. This review will highlight recent advances in the development of novel anabolic approaches for treatment of osteoporosis, such as parathyroid hormone (PTH), calcium sensing receptor modulators, statins and prostanoid receptor agonists. Selected antiresorptive targets (cathepsin K inhibitors and vitronectin receptor antagonists) will also be surveyed.

AB - Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones. It causes a significant amount of morbidity and mortality in patients and is often only diagnosed after a fracture occurs. This review will highlight recent advances in the development of novel anabolic approaches for treatment of osteoporosis, such as parathyroid hormone (PTH), calcium sensing receptor modulators, statins and prostanoid receptor agonists. Selected antiresorptive targets (cathepsin K inhibitors and vitronectin receptor antagonists) will also be surveyed.

KW - Anabolic therapy

KW - Calcium sensing receptor

KW - Cathepsin K inhibitors

KW - Osteoporosis

KW - Parathyroid hormone

KW - Prostanoids

KW - Statins

KW - Vitronectin antagonists

UR - http://www.scopus.com/inward/record.url?scp=0036654299&partnerID=8YFLogxK

M3 - Review article

C2 - 12197306

AN - SCOPUS:0036654299

VL - 5

SP - 477

EP - 486

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 4

ER -